Washington, DC – September 7, 2016 – Today the Cancer Moonshot Blue Ribbon Panel, comprised of 28 world-class leaders from science, research, and patient advocacy, including Friends of Cancer Research’s (Friends) Chair and Founder Ellen Sigal, presented their recommendations for accelerating cancer research to the President’s National Cancer Advisory Board. The Blue Ribbon Panel authored a report at the request of the Vice President, which outlines areas of urgent action to accelerate the field of cancer research.
Friends supports the Blue Ribbon Panel’s exciting and powerful recommendations. Implementation of the recommendations through the merger of science, technology, advocacy, social science, and data, will help speed cancer research to achieve in 5 years what would normally take 10. The recommendations are patient focused and emphasize the inclusion of the whole cancer community through expanding the reach of and access to clinical trials.
“It is vital that we start incorporating the patient perspective into cancer research so that we can address all aspects of the disease and conquer it,” Sigal said. “I’m honored to be a part of the Blue Ribbon Panel and look forward to the recommendations being approved and implemented so that we can start the accelerated advancement of cancer research now.”
“Without the support and leadership of Vice President Biden, the Blue Ribbon Panel would not have been able to work together to quickly and effectively compile these revolutionary recommendations,” Sigal stated.
Friends of Cancer Research thanks Vice President Biden for championing the effort and aiming to implement the Blue Ribbon Panel’s recommendations so that we can conquer cancer as we know it. To view the Blue Ribbon Panel’s report and recommendations in full, please visit: www.cancer.gov/brp.
About Friends of Cancer Research
Friends of Cancer Research (Friends) drives collaboration among partners from every healthcare sector to power advances in science, policy and regulation that speed life-saving treatments to patients. For more information, please visit www.focr.org.